Las Vegas, NV -- (SBWIRE) -- 12/26/2012 -- Cellceutix Corp (OTC:CTIX) has been making a highly explosive move up in recent trading sessions driven by continued massive demand for the stock which was only hightened by the recent NY times article on called genetic gamble; new approaches to fighting cancer.
As most investors are aware; Cellceutix Corp is fast turning into the most exciting story in penny stocks; potentially sitting on the multi-billion dollar drug-resistant cancers market the Company's stock has been making a highly explosive move up from its $0.50 base to recent highs over $2.25 per share.
Cellceutix Corp. is an emerging bio-pharmaceutical company based in Beverly, Massachusetts. The Company's CSO, Dr. Krishna Menon is a real whiz; he played key roles in developing two blockbuster cancer drugs; Gemzar and Alimta for Eli Lilly & Co.(NYSE:LLY) back in the 90's.
Kevetrin(TM), an anti-cancer drug that regulates the p53 pathway and attacks drug-resistant cancers could easily trump them all and make Cellceutix a multi-billion dollar Company.
Regulating the p53 pathway has long been the holy grail of cancer research and big pharma has spent hundreds of millions of dollars researching ways to achieve this with little success. It is beginning to look like Kevetrin(TM) has done just this; extensive preclinical research on Kevetrin shows the re-activation of p53 across a wide spectrum of cancer lines including colon, lung, breast and pancreatic cancers.
To find out what OTCMAGIC projects for Cellceutix Corp both short term and long term, please go here: CTIX
OTCMAGIC Spends all day scouring the markets for the next huge Penny Stocks Winner. Investors have come to trust us for our up to date commentary on all hot stocks so please visit OTCMAGIC right now and see what it’s all about for yourself! At 30,000 Visitors a Month and growing rapidly OTCMAGIC is the hottest thing in Penny Stocks!
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PLEASE NOTE: OTCMagic.com employees are not registered as an Investment Advisor in any jurisdiction whatsoever. Full disclaimer can be read at http://OTCMagic.com/disclaimer. Release of Liability: Through use of this website viewing or using you agree to hold OTCMagic.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss monetary or otherwise, damage monetary or otherwise, or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. OTCMagic.com affiliates may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCMagic.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCMagic.com. We make no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. This is not a solicitation to buy or sell any securities. Any claims or Statements should be deemed hypothetical. OTCMagic.com, nor any of its affiliates are not registered investment advisors or broker dealers
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)